CD274 and hypophysitis: The incidence of hypophysitis was highest with combination therapy (6.4%), compared to 3.2% with anti-CTLA-4 therapy, 0.4% with anti-PD-1 therapy, and less than 0.1% with anti-PD-L1 therapy [6].